Drug intelligence / Profile preview

citalopram + citicoline

Development stage: Unknown
Lead developer: Ferrer
Modality: Small Molecules
Administration: Intraperitoneal, Oral

Overview

A combination of citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and citicoline, a nootropic compound. This combination has demonstrated synergistic effects in treating anxiety and depression. Citalopram works by inhibiting serotonin reuptake, while citicoline serves as an intermediate in the synthesis of phosphatidylcholine, a major constituent of brain tissue. The combination has shown enhanced efficacy in treating major depressive disorder compared to citalopram alone, with significantly higher remission rates in clinical trials.

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on citalopram + citicoline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on citalopram + citicoline.

Explore the full profile